Myricx Bio

Myricx Bio is a private, preclinical-stage biotechnology company pioneering a first-in-class approach to antibody-drug conjugates (ADCs) by utilizing N-myristoyltransferase (NMT) inhibitors as cytotoxic payloads. Founded in 2020 and headquartered in London with a US presence in Boston, the company is backed by a strong syndicate of life science investors including Abingworth, Brandon Capital, and Novo Holdings. Under new CEO Mohit Rawat, who brings significant ADC and transaction expertise from Fusion Pharmaceuticals, Myricx is advancing its platform, which has shown compelling preclinical efficacy and safety across multiple solid tumor models.

Proprietary platform for developing N-myristoyltransferase (NMT) inhibitors as novel cytotoxic payloads for Antibody-Drug Conjugates (ADCs).

Myricx competes in the crowded and innovative ADC payload space, facing companies developing novel warheads like immunostimulants, protein degraders, and other enzyme inhibitors. Its differentiation hinges on the first-in-class NMT inhibition mechanism. It also competes for funding and partnership attention with other preclinical/platform biotechs.